Biobankonomics

A taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research

Joyce Rogers, Todd Carolin, Jimmie Vaught, Carolyn Compton

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Investments in medical research and development enable the scientific progress that influences our society's body of knowledge about disease, the quality of health care, and our quality of life. Critical components of these investments include the technological and human capital factors rooted in human specimen biobanking, which can be considered foundational to driving post genomic scientific and medical research. Their importance to cancer research, information-based medicine, and quality of health care are becoming increasingly recognized by pharmaceutical companies, non profit foundations, academic researchers, and government research agencies. However, the failure to standardize tissue collection, handling, processing, and preservation so that data can be directly compared between specimen sets, as well as insufficient leveraging of the highest quality tissue samples and associated data across an array of research needs, have strained economies of scale for the biobanking field. Although existing biobanks for private research contribute economic benefits to stakeholders that can be easily substantiated, little has been published to demonstrate the positive outcomes generated from the use, application, and dissemination of their resources more broadly. Through the use of analogous examples, this article presents a rationale for how standardization and consolidation of biobanking resources would contribute to the realization of budget savings, cost avoidances, process efficiencies, and other financial impacts to both the research community and the public. A number of areas are examined, including laboratory analysis efficiencies, data modeling accuracy, infrastructure cost savings, reduced clinical trials evaluation costs, improvements in patient diagnosis, and the potential impact on industry professionalization and job creation. Areas for further study are also outlined. Published by Oxford University Press 2011.

Original languageEnglish (US)
Pages (from-to)32-38
Number of pages7
JournalJournal of the National Cancer Institute. Monographs
Issue number42
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Translational Medical Research
Economics
Research
Cost Savings
Quality of Health Care
Biomedical Research
Government Agencies
Budgets
Industry
Quality of Life
Research Personnel
Medicine
Clinical Trials
Costs and Cost Analysis
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

@article{5b90c75033c94b87ac8da82f7e283afa,
title = "Biobankonomics: A taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research",
abstract = "Investments in medical research and development enable the scientific progress that influences our society's body of knowledge about disease, the quality of health care, and our quality of life. Critical components of these investments include the technological and human capital factors rooted in human specimen biobanking, which can be considered foundational to driving post genomic scientific and medical research. Their importance to cancer research, information-based medicine, and quality of health care are becoming increasingly recognized by pharmaceutical companies, non profit foundations, academic researchers, and government research agencies. However, the failure to standardize tissue collection, handling, processing, and preservation so that data can be directly compared between specimen sets, as well as insufficient leveraging of the highest quality tissue samples and associated data across an array of research needs, have strained economies of scale for the biobanking field. Although existing biobanks for private research contribute economic benefits to stakeholders that can be easily substantiated, little has been published to demonstrate the positive outcomes generated from the use, application, and dissemination of their resources more broadly. Through the use of analogous examples, this article presents a rationale for how standardization and consolidation of biobanking resources would contribute to the realization of budget savings, cost avoidances, process efficiencies, and other financial impacts to both the research community and the public. A number of areas are examined, including laboratory analysis efficiencies, data modeling accuracy, infrastructure cost savings, reduced clinical trials evaluation costs, improvements in patient diagnosis, and the potential impact on industry professionalization and job creation. Areas for further study are also outlined. Published by Oxford University Press 2011.",
author = "Joyce Rogers and Todd Carolin and Jimmie Vaught and Carolyn Compton",
year = "2011",
doi = "10.1093/jncimonographs/lgr010",
language = "English (US)",
pages = "32--38",
journal = "NCI Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "42",

}

TY - JOUR

T1 - Biobankonomics

T2 - A taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research

AU - Rogers, Joyce

AU - Carolin, Todd

AU - Vaught, Jimmie

AU - Compton, Carolyn

PY - 2011

Y1 - 2011

N2 - Investments in medical research and development enable the scientific progress that influences our society's body of knowledge about disease, the quality of health care, and our quality of life. Critical components of these investments include the technological and human capital factors rooted in human specimen biobanking, which can be considered foundational to driving post genomic scientific and medical research. Their importance to cancer research, information-based medicine, and quality of health care are becoming increasingly recognized by pharmaceutical companies, non profit foundations, academic researchers, and government research agencies. However, the failure to standardize tissue collection, handling, processing, and preservation so that data can be directly compared between specimen sets, as well as insufficient leveraging of the highest quality tissue samples and associated data across an array of research needs, have strained economies of scale for the biobanking field. Although existing biobanks for private research contribute economic benefits to stakeholders that can be easily substantiated, little has been published to demonstrate the positive outcomes generated from the use, application, and dissemination of their resources more broadly. Through the use of analogous examples, this article presents a rationale for how standardization and consolidation of biobanking resources would contribute to the realization of budget savings, cost avoidances, process efficiencies, and other financial impacts to both the research community and the public. A number of areas are examined, including laboratory analysis efficiencies, data modeling accuracy, infrastructure cost savings, reduced clinical trials evaluation costs, improvements in patient diagnosis, and the potential impact on industry professionalization and job creation. Areas for further study are also outlined. Published by Oxford University Press 2011.

AB - Investments in medical research and development enable the scientific progress that influences our society's body of knowledge about disease, the quality of health care, and our quality of life. Critical components of these investments include the technological and human capital factors rooted in human specimen biobanking, which can be considered foundational to driving post genomic scientific and medical research. Their importance to cancer research, information-based medicine, and quality of health care are becoming increasingly recognized by pharmaceutical companies, non profit foundations, academic researchers, and government research agencies. However, the failure to standardize tissue collection, handling, processing, and preservation so that data can be directly compared between specimen sets, as well as insufficient leveraging of the highest quality tissue samples and associated data across an array of research needs, have strained economies of scale for the biobanking field. Although existing biobanks for private research contribute economic benefits to stakeholders that can be easily substantiated, little has been published to demonstrate the positive outcomes generated from the use, application, and dissemination of their resources more broadly. Through the use of analogous examples, this article presents a rationale for how standardization and consolidation of biobanking resources would contribute to the realization of budget savings, cost avoidances, process efficiencies, and other financial impacts to both the research community and the public. A number of areas are examined, including laboratory analysis efficiencies, data modeling accuracy, infrastructure cost savings, reduced clinical trials evaluation costs, improvements in patient diagnosis, and the potential impact on industry professionalization and job creation. Areas for further study are also outlined. Published by Oxford University Press 2011.

UR - http://www.scopus.com/inward/record.url?scp=80053417661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053417661&partnerID=8YFLogxK

U2 - 10.1093/jncimonographs/lgr010

DO - 10.1093/jncimonographs/lgr010

M3 - Article

SP - 32

EP - 38

JO - NCI Monographs

JF - NCI Monographs

SN - 1052-6773

IS - 42

ER -